DelveInsight’s “Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Multiple System Atrophy, historical and forecasted epidemiology as well as the Multiple System Atrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Multiple System Atrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple System Atrophy Market Forecast
Some of the key facts of the Multiple System Atrophy Market Report:
-
The Multiple System Atrophy market size was valued approximately ~USD 182 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In July 2024, Alterity Therapeutics announced promising interim results from the Phase II trial of ATH434 for Multiple System Atrophy. The analysis incorporated clinical and biomarker data from seven participants who were treated for six months, as well as neuroimaging data from three individuals who received treatment for 12 months. Remarkably, 43% of participants showed improved scores on the UMSARS Activities of Daily Living Scale after six months, indicating a decrease in disability.
-
In 2023, the US held the largest market size for MSA among the 7MM, with an estimated value of around USD 120 million. This figure is projected to grow at a compound annual growth rate (CAGR) of 3.8% by 2034.
-
Among EU countries, Germany reported the highest market size for MSA, reaching nearly USD 7 million in 2023, whereas Spain had the lowest market size at approximately USD 4 million for the same year.
-
The market size for MSA in Japan was estimated to be approximately USD 24 million in 2023.
-
The anticipated launch of new therapies, including Ampreloxetine (TD-9855), Lu AF82422, and ATH434, among others, is expected to impact the total market size of MSA in the coming years.
-
In 2023, the total diagnosed prevalence of Multiple System Atrophy (MSA) was around 51,200 across the 7MM, and this number is anticipated to rise by 2034.
-
In DelveInsight’s assessment, the estimated number of diagnosed prevalent cases of MSA in 2023 was highest in the US among the 7MM, totaling nearly 24,500 cases, with expectations for this figure to rise by 2034.
-
In 2023, Japan represented around 24% of the diagnosed prevalent cases of MSA within the 7MM. These cases are expected to rise significantly at a robust CAGR throughout the forecast period.
-
In the US, the estimated diagnosed prevalent cases in 2023 by age group were approximately 300 for ages 30-39, around 4,300 for ages 40-49, about 11,200 for ages 50-59, roughly 6,400 for ages 60-79, and approximately 2,300 for individuals aged 80 and older.
-
Among European countries, Germany reported the highest number of diagnosed prevalent cases of dementia, totaling around 3,800. Within these cases, males were more significantly affected by MSA, accounting for approximately 2,100 cases, while females represented about 1,700 cases.
-
In 2023, Japan’s age-specific diagnosed prevalence of MSA was greatest in the 60-79 age group, with approximately 6,300 cases. This was followed by the 50-59 age group with about 4,200 cases and the 40-49 age group with roughly 1,400 cases.
-
Key Multiple System Atrophy Companies: Alterity Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others
-
Key Multiple System Atrophy Therapies: ATH434-201/-202, Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, Verdiperstat, TAK-341, KM-819, rasagiline mesylate, Safinamide Methanesulfonate, AZD3241, NBMI, hOMSC300, DaTSCAN™ Ioflupane, Droxidopa, and others
-
The Multiple System Atrophy epidemiology based on gender analyzed that males are most commonly affected as compare females in case of Multiple System Atrophy (MSA) in the 7MM
-
The Multiple System Atrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple System Atrophy pipeline products will significantly revolutionize the Multiple System Atrophy market dynamics.
Multiple System Atrophy Overview
Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects the body’s autonomic functions, such as blood pressure, heart rate, bladder function, and digestion, as well as motor control. MSA is characterized by a combination of symptoms similar to those of Parkinson’s disease, cerebellar ataxia, and autonomic failure.
Get a Free sample for the Multiple System Atrophy Market Report:
https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-market
Multiple System Atrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Multiple System Atrophy Epidemiology Segmentation:
The Multiple System Atrophy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Multiple System Atrophy
-
Prevalent Cases of Multiple System Atrophy by severity
-
Gender-specific Prevalence of Multiple System Atrophy
-
Diagnosed Cases of Episodic and Chronic Multiple System Atrophy
Download the report to understand which factors are driving Multiple System Atrophy epidemiology trends @ Multiple System Atrophy Epidemiology Forecast
Multiple System Atrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple System Atrophy market or expected to get launched during the study period. The analysis covers Multiple System Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Multiple System Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Multiple System Atrophy Therapies and Key Companies
-
ATH434-201/-202: Alterity Therapeutics
-
Lu AF82422: H Lundbeck A/S
-
Ampreloxetine (TD-9855): Theravance Biopharma
-
AAV2-GDNF Gene Therapy: Brain Neurotherapy Bio, Inc
-
ION464: Ionis Pharmaceuticals, Inc.
-
ATH434: Alterity Therapeutics
-
Verdiperstat: Biohaven Pharmaceuticals, Inc.
-
TAK-341: Takeda
-
KM-819: Kainos Medicine Inc.
-
rasagiline mesylate: Teva Branded Pharma
-
Safinamide Methanesulfonate: Zambon SpA
-
AZD3241: AstraZeneca
-
NBMI: EmeraMed
-
hOMSC300: Cytora Ltd.
-
DaTSCAN™ Ioflupane: GE Healthcare
-
Droxidopa: Chelsea Therapeutics
Discover more about therapies set to grab major Multiple System Atrophy market share @ Multiple System Atrophy Treatment Market
Multiple System Atrophy Market Drivers
-
Prospect for a robust pipeline
-
New Pre-clinical MoAs
-
Increase in Multiple System Atrophy research
-
Regulatory designations
Multiple System Atrophy Market Barriers
-
Launch of generics
-
Diagnostic barrier
-
Limited clinical research
Scope of the Multiple System Atrophy Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Multiple System Atrophy Companies: Alterity Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others
-
Key Multiple System Atrophy Therapies: ATH434-201/-202, Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, Verdiperstat, TAK-341, KM-819, rasagiline mesylate, Safinamide Methanesulfonate, AZD3241, NBMI, hOMSC300, DaTSCAN™ Ioflupane, Droxidopa, and others
-
Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies
-
Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Multiple System Atrophy Unmet Needs, KOL’s views, Analyst’s views, Multiple System Atrophy Market Access and Reimbursement
To know more about Multiple System Atrophy companies working in the treatment market, visit @ Multiple System Atrophy Clinical Trials and Therapeutic Assessment
Table of Contents
1. Multiple System Atrophy Market Report Introduction
2. Executive Summary for Multiple System Atrophy
3. SWOT analysis of Multiple System Atrophy
4. Multiple System Atrophy Patient Share (%) Overview at a Glance
5. Multiple System Atrophy Market Overview at a Glance
6. Multiple System Atrophy Disease Background and Overview
7. Multiple System Atrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Multiple System Atrophy
9. Multiple System Atrophy Current Treatment and Medical Practices
10. Multiple System Atrophy Unmet Needs
11. Multiple System Atrophy Emerging Therapies
12. Multiple System Atrophy Market Outlook
13. Country-Wise Multiple System Atrophy Market Analysis (2020–2034)
14. Multiple System Atrophy Market Access and Reimbursement of Therapies
15. Multiple System Atrophy Market Drivers
16. Multiple System Atrophy Market Barriers
17. Multiple System Atrophy Appendix
18. Multiple System Atrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma